recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) (DBCOND0144294)

Identifiers

Synonyms

Recurrent Head and Neck Squamous Cell Cancer / Recurrent Head and Neck Squamous Cell Carcinoma / Recurrent Squamous Cell Carcinoma of the Head and Neck / Recurrent Squamous Cell Carcinoma of the Head or Neck

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Cetuximab	An endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.	Epidermal growth factor receptortarget Low affinity immunoglobulin gamma Fc region receptor III-Btarget Complement C1q subcomponent subunit Atarget Complement C1q subcomponent subunit Btarget Complement C1q subcomponent subunit Ctarget Low affinity immunoglobulin gamma Fc region receptor III-Atarget High affinity immunoglobulin gamma Fc receptor Itarget Low affinity immunoglobulin gamma Fc region receptor II-atarget
Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03522584	Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Durvalumab Tremelimumab	treatment	1 / 2	terminated
NCT06064877	A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma	Cetuximab Ficlatuzumab	treatment	3	recruiting
NCT05901545	Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer	Panitumumab	treatment	1	recruiting
NCT04282109	Study to Assess the Efficacy and Safety of Nivolumab in Combination with Paclitaxel in Subjects with Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)	Cetuximab Nivolumab Paclitaxel	treatment	2	completed
NCT05980000	Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma	Pembrolizumab Ramucirumab	treatment	2	recruiting
NCT04220775	Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer	Bintrafusp alfa	treatment	1 / 2	terminated
NCT05945875	Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer	Panitumumab	diagnostic	1	recruiting
NCT05156970	Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC	Camrelizumab Carboplatin Cisplatin Docetaxel Rivoceranib	treatment	2	recruiting
NCT05743270	Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	Nivolumab	treatment	2	withdrawn
NCT03422536	Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma	Cetuximab Ficlatuzumab	treatment	2	completed
NCT03813836	Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC	Pembrolizumab	treatment	2	recruiting
NCT05172258	Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	Ipatasertib Pembrolizumab	treatment	2	recruiting
NCT06465030	Identification of Pattern and Factors Affecting Recurrence in Head and Neck Carcinoma	No drug interventions	Not Available	Not Available	recruiting
NCT06239220	PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC	CD-16 NK-92 cells Cetuximab Nogapendekin alfa	treatment	2	recruiting
NCT00494182	Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	Carboplatin Paclitaxel Sorafenib	treatment	2	active_not_recruiting
NCT04576091	Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer	Elimusertib Pembrolizumab	treatment	1	active_not_recruiting
NCT04454489	Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition	Pembrolizumab	treatment	2	suspended
NCT04007744	Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	Pembrolizumab Sonidegib	treatment	1	recruiting
NCT04671667	Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma	Carboplatin Chloride ion Cisplatin Pembrolizumab Platinum	treatment	2	recruiting
NCT04305795	An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors	Cemiplimab Cetuximab sarotalocan Pembrolizumab	treatment	1 / 2	active_not_recruiting
NCT03032250	Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer	No drug interventions	supportive_care	Not Available	completed
NCT04862650	Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Carboplatin Cemiplimab Paclitaxel	treatment	2	recruiting
NCT04588038	NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery	Efineptakin alfa	treatment	1	recruiting
NCT02955290	CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer	Incomplete Freund's adjuvant Nepidermin Nivolumab Pembrolizumab	treatment	1 / 2	recruiting
NCT04375384	Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer	Cetuximab	treatment	2	recruiting
NCT04643379	Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma	Carboplatin Olaparib Pembrolizumab	treatment	2	active_not_recruiting
NCT03229278	Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	Nivolumab Pembrolizumab	treatment	1	completed
NCT06265285	Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	Nivolumab	health_services_research	2	recruiting
NCT01602315	A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Alpelisib Cetuximab	treatment	1 / 2	terminated
NCT05063552	Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers	Atezolizumab Bevacizumab Carboplatin Cetuximab Chloride ion Cisplatin Docetaxel Platinum	treatment	2 / 3	recruiting
NCT05726370	Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC	Carboplatin Cisplatin Docetaxel Pembrolizumab	treatment	2	recruiting
NCT03521570	Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer	Nivolumab	treatment	2	active_not_recruiting
NCT04834349	Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer	Pembrolizumab	treatment	2	withdrawn
NCT03468218	Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer	Cabozantinib Pembrolizumab	treatment	2	active_not_recruiting
NCT01468896	Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery	Cetuximab Edodekin alfa Interleukin-12 human recombinant Natural Killer Cell	treatment	1 / 2	active_not_recruiting
NCT03823131	Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat	Epacadostat Pembrolizumab Tavokinogene telseplasmid	treatment	2	terminated
NCT05359692	INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Ragifilimab Retifanlimab	treatment	2	withdrawn
NCT04290546	CIML NK Cell in Head & Neck Cancer	Cetuximab Ipilimumab Nogapendekin alfa	treatment	1	recruiting
NCT04862455	NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer	Hafnium oxide Pembrolizumab	treatment	2	recruiting
NCT05783921	A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma	Carboplatin Cisplatin Paclitaxel Penpulimab	treatment	1 / 2	recruiting
NCT05057247	Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC	Docetaxel Duvelisib	treatment	2	active_not_recruiting
NCT06357858	ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck	Cedazuridine Decitabine Nivolumab	treatment	1	withdrawn
NCT05271604	A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Cetuximab Evalstotug Ozuriftamab vedotin Pembrolizumab	treatment	2	recruiting
NCT03667482	Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer	Cabozantinib Cetuximab	treatment	1	completed
NCT03652233	Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Afatinib Nivolumab	treatment	1	withdrawn